FDA grants priority review to Merck’s KEYTRUDA and KEYTRUDA QLEX combos with Padcev for muscle-invasive bladder cancer

The submissions are supported by data from the Phase 3 KEYNOTE-905 trial

Pimicotinib delivers lasting tumor responses and sustained symptom relief in TGCT patients

Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile

FDA approves Roche’s kidney inflammation drug

Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study

AstraZeneca’s Imfinzi cuts death risk by 32% in high-risk non-muscle-invasive bladder cancer

Adding one year of Imfinzi treatment to Bacillus Calmette-Guérin (BCG) induction and maintenance therapy delivered an early and sustained disease-free survival benefit vs. BCG alone

Johnson & Johnson’s Rybrevant shows 45% response rate in HNSCC

Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab

KEYTRUDA + LENVIMA shows durable 5-year survival benefit in advanced endometrial cancer

The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy

Cupid achieves CE (EU IVDR) certification for pregnancy and syphilis test kits

IOL Chemicals receives EDQM certificate for Pantoprazole Sodium Sesquihydrate Process-III

Pantoprazole sodium is a proton pump inhibitor reduces stomach acid

Merck’s DOR/ISL regimen shows minimal impact on weight and lipids in phase 3 HIV studies

These findings follow positive Phase 3 results presented earlier this year

Bristol Myers Squibb showcases transformative advances across oncology portfolio at ESMO 2025